AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04989946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: standard Gonadotropin-releasing hormone (GnRH) antagonist
Study NCT04989946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: standard Gonadotropin-releasing hormone (GnRH) antagonist
Study NCT04989946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-AR
Description: DNA vaccine encoding androgen receptor ligand-binding domain
Study NCT04989946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
Study NCT04989946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a human PD-1 blocking antibody approved for the treatment of patients with non-small cell lung cancer, cutaneous squamous cell carcinoma, and locally advanced basal cell carcinoma.
Study NCT04989946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Lymphocyte activation gene-3 (LAG-3) is a protein that is upregulated on activated CD4+ and CD8+ T cells following T-cell receptor engagement. Binding of LAG-3 to MHC II on professional antigen-presenting cells suppresses the proliferation, activation, and cytokine secretion of T cells. Fianlimab is a human IgG4 antibody to lymphocyte activation gene-3 (LAG-3) that blocks LAG-3/MHC II-mediated T-cell inhibition.
Study NCT04989946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLT PET/CT
Description: Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43
Study NCT04989946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT PET/CT
Description: Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43
Study NCT06052410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early Intervention
Description: Based on the principles of the Goal, Activity and Motor Enrichment (GAME) approach, which is an evidence-based early intervention approach for children at risk of developmental delay between 24-36 months, activity-based training is aimed at the development of sensory and cognitive skills in addition to the training of motor skills, which are intensively discussed in the content of the approach. Individualized early occupational therapy intervention including strategies was implemented.
Study NCT06052410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home Programme
Description: For the control group, evaluation tests were first applied to the babies selected by simple random sampling method. An individualized home program was given according to the evaluation results. Home programs include activities for every skill area and were prepared together with the parents, taking into account the criteria suggested for the success of the home program. Based on these criteria, it was checked whether the family had received another home program, and while preparing the program, care was taken not to overload the parents, importance was given to the family's willingness to receive the home program, activities and goals were decided in cooperation with the parent, thus facilitating the applicability of the activities in daily life, ensuring that the number of activities was 6. Care was taken to ensure that the activity was not too much, the parent was given the necessary time to implement the program, and a phone call was made to the parent every 3 weeks.
Study NCT04994457 — intervention group
Intervention type: DEVICE
Intervention: Virtual Reality Visual Field
Description: A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses
Study NCT04994457 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard Automated Perimetry
Description: Standard of care perimeter
Study NCT05366777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen/ibuprofen fixed-dose combination
Description: Intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) fixed-dose combination (total 100 ml)
Study NCT05366777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 ml of normal saline
Study NCT06078904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: Colchicine 0.5 MG, one pill a day, oral intake
Study NCT06078904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.375 MG
Description: Colchicine 0.375 MG, one pill a day, oral intake
Study NCT06078904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.25 MG
Description: Colchicine 0.25 MG, one pill a day, oral intake
Study NCT06078904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one pill a day, oral intake
Study NCT06059495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: After inclusion: dostarlimab 500mg IV 30min q3w (± 2-3 days) for 4 cycles (C1-C4)~Then:~At wk12 • If cCR: dostarlimab 1000mg q6w for 2 cycles (C5-C6)~• If downstaging at UGI endoscopy, and no disease progression (PD)/or mets on TAP-CT, \<3 biopsies with tumor cells: dostarlimab 500mg q3w for 4 cycles (C5-C8)~• If loco/loco-regional PD on TAP-CT, macroscopic tumor on UGI endoscopy, no distant mets, and >2 positive biopsies at wk12 followed by surgery and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 6 cycles (C5-C10)~At 24wk~• If cCR at 12 and 24 wks: dostarlimab 1000mg q6w for 4 cycles (C7-C10)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with \<3 biopsies with tumor cells at wk12 and cCR: dostarlimab 1000mg q6w for 4 cycles (C9-C12)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with and no cCR, surgery will be proposed and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 4 cycles (C9-C12)
Study NCT05844813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin+Ifosfamide+Anlotinib(AI+A)
Description: Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks \* 3 Circles
Study NCT05844813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Surgery
Description: Radical sarcoma resectional surgery
Study NCT05844813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Surgery
Description: Radical sarcoma resectional surgery
Study NCT06303739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: 25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.
Study NCT06303739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: psilocybin
Description: 25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.
Study NCT05330065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and camrelizumab
Description: Stage 1 was classical 3+3 dose escalation with pts assigned to one of the following 3 cohorts, Cohort A:Avastin 5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort B:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort C:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 200mg once every 2 weeks.DLT was observed for 28 days.
Study NCT04866797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cyclic merocyanine
Description: long-UVA absorber
Study NCT04866797 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04760418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
Description: A 12-session integrated cognitive behavioral therapy for posttraumatic stress disorder and substance use
Study NCT06442150 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-Calorie Medicine Diet
Description: Low-Calorie Medicine Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
Study NCT06442150 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Low-Calorie Diet
Description: Low-Calorie Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
Study NCT05066724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: 400 mg total daily dose Centanafadine Sustained Release, oral tablets
Study NCT05777226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epalrestat
Description: Patients in the treatment group are intervened with Epalrestat tablets.
Study NCT05737082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2201
Description: Take 2 tablets once per period
Study NCT05737082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2205
Description: Take 2 tablets once per period
Study NCT05737082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2206
Description: Take 1 tablet once per period
Study NCT05060016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Intravenous (IV) infusion
Study NCT06652971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379
Description: QD, PO
Study NCT05904730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day)
Study NCT06652815 — intervention group
Intervention type: BEHAVIORAL
Intervention: Suicide ideation or suicide attempt
Description: Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study. socio- demographics details will also be gathered. Following this Depression, Anxiety and Stress Scale (DASS-21), Wisconsin Card Sorting Test (WCST), Metacognitions Scale (MCQ-30) and Stigma of Suicide Scale (SOSS) will be administered.
Study NCT05972772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycyclin
Description: 100-mg film-coated tablets; Pfizer
Study NCT05972772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 250-mg capsules; Pfizer
Study NCT06439082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.
Study NCT06439082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.
Study NCT05385575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (0.1mg)
Description: The participants will receive assigned single dose of KN056 on Day 1
Study NCT05385575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (0.3mg)
Description: The participants will receive assigned single dose of KN056 on Day 1
Study NCT05385575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (1.0mg)
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study NCT05385575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (3.0mg)
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study NCT05385575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (6.0mg)
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study NCT05385575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (12.0mg)
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study NCT05385575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (18.0mg)
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study NCT06590428 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Drug Monitoring for Linezolid
Description: TDM with dose adjustment for trough concentration >2.5 mg/L LZD
Study NCT05258279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsule once daily
Study NCT05258279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion Q3W
Study NCT05258279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion Q3W
Study NCT06328556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use.
Study NCT06328556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection
Description: Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
Study NCT06669169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jia Shen Tablet Placebo
Description: Jia Shen Tablet Placebo contains 4 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
Study NCT06247605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL8326 tablets
Description: 10mg/tablet, Oral administration, once daily.
Study NCT06247605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration, once daily.
Study NCT05020665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: 400 mg, Orally as tablets
Study NCT05020665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally as tablets
Study NCT05020665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Continuous infusion
Study NCT05020665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: Continuous infusion
Study NCT05020665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline
Description: Either daunorubicin or idarubicin was administered via slow intravenous (IV) push
Study NCT05020665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anthracycline
Description: Either daunorubicin or idarubicin was administered via slow intravenous (IV) push
Study NCT04728841 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Injection of GS001
Description: Patients will be enrolled sequentially every 3 weeks or more between cohorts. Dose escalation may occur after a single patient has been safely dosed if the resulting FVIII activity at Week 3 is \< 5 IU/dL.The dose levels are as follows:~1. 2×10\^12 vg/kg~2. 6×10\^12vg/kg or other recommended doses~3. 2×10\^13 vg/kg or other recommended doses
Study NCT05007431 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Data collection will be carried out by hetero-questionnaire carried out in the presence of the questioned.
Study NCT04974996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Description: Intravenous (IV) infusion
Study NCT04974996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally via tablet or capsule
Study NCT04974996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) infusion
Study NCT04974996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous (IV) infusion
Study NCT04974996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenous (IV) infusion
Study NCT04974996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Intravenous (IV) infusion
Study NCT06099522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Description: The treatment is a newly developed iCBT 8 module program, with interventions targeting gambling-related loss of control, through 4 clinical processes: Gambling triggers, Gambling-related anticipation, the Gambling zone and Chasing behaviors. The treatment will be delivered with therapist support.
Study NCT06669169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Jia Shen Tablet
Description: Low dose Jia Shen Tablet contains 2 tablets (0.47 g per tablet) and 2 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
Study NCT06669169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Jia Shen Tablet
Description: High dose Jia Shen Tablet contains 4 tablets (0.47 g per tablet),take orally, 2 times a day for 12 weeks
Study NCT06670235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upright Birthing Position
Description: This intervention involves encouraging participants to use an upright position during labor and delivery, which may include : squatting, based on their preference and comfort level. Healthcare staff will support the participants in maintaining an upright position throughout labor as much as possible to evaluate its effects on maternal and newborn outcomes.
Study NCT06670235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lithotomy Birthing Position
Description: Participants in this arm will be positioned in the lithotomy position during labor and delivery, which is a common practice in clinical settings. In this position, the mother lies on her back with her legs supported in stirrups. This intervention serves as the control condition to provide a baseline comparison for evaluating outcomes against the upright birthing position.
Study NCT06607627 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gefurulimab
Description: Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.
Study NCT06140199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pit-picking surgery
Description: Patients are placed in left-side position. After shaving, cleaning and scrubbing of the skin with alcoholic chlorhexidine, double strong tape is placed on the right buttock in order to increase exposure. Local anaesthesia is administered before incision with 20 ml xylocaine or lidocaine 1-2%. In principle, all sinusoidal pits are cut out with a margin of at least 1 mm with a biopsy core punch (4 mm, 6 mm or 8 mm depending on pit size) or an oval excision of the pits is performed. Hair and debris is removed from the sinus tracts with a small surgical spoon or mosquito clamp. Rigorous de-epithelialisation of the underlying sinus is performed with the spoon through every pit, whilst removing even more debris and hairs. At the end of the procedure a debris washout is performed with saline solution, the wounds are left open for secondary healing and sterile dressings are applied.
Study NCT06140199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pit-picking surgery with Sinus Laser assisted Closure
Description: The pit picking procedure is described above. Subsequently, a radial diode laser probe at 1470 nm wavelength is used for delivering homogeneous (360 degrees) energy to the surrounding epithelium. The laser energy is 13 Joule, given continuously. First, a 'preparatory laser treatment' is performed to extract any missed hairs or debris, after which the sinus tracts are cleansed with a surgical spoon again. During the following definitive procedure, the probe is withdrawn at an approximate speed of 1 cm per three seconds, causing the small sinus tracts to shrink and close. Large sinus tracts remain open because very large sinus tracts or cavities cannot be closed with the 3mm laser fibre. The injury to the endothelium will cause granulation and create oedema for collapsing of the tract. The remaining open wounds are left open for secondary healing and sterile dressings are applied.
Study NCT05338333 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal contact lenses
Description: Investigational frequent replacement soft contact lens indicated for the optical correction of presbyopia
Study NCT05338333 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Commercially available frequent replacement soft contact lens indicated for the optical correction of presbyopia
Study NCT05338333 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE®
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution
Study NCT03201939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: ACE-inhibitor (lisinopril)(intervention arm
Study NCT03201939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Comparator placebo (control arm)